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Abstract Bcl10, a caspase recruitment domain (CARD)-
containing protein identified from a breakpoint in mucosa-
associated lymphoid tissue (MALT) B lymphomas, is essential
for antigen-receptor-mediated nuclear factor UB (NF-UB)
activation in lymphocytes. We have identified a novel CARD-
containing protein and interaction partner of Bcl10, named
Carma1. Carma1 is predominantly expressed in lymphocytes and
represents a new member of the membrane-associated guanylate
kinase family. Carma1 binds Bcl10 via its CARD motif and
induces translocation of Bcl10 from the cytoplasm into peri-
nuclear structures. Moreover, expression of Carma1 induces
phosphorylation of Bcl10 and activation of the transcription
factor NF-UB. We propose that Carma1 is a crucial component
of a novel Bcl10-dependent signaling pathway in T-cells that
leads to the activation of NF-UB. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Mucosa-associated lymphoid tissue (MALT) lymphomas
most frequently involve the gastrointestinal tract and are the
most common subset of extranodal non-Hodgkin lymphoma.
Chromosomal translocation t(1;14)(p22;q32) is recurrent in
MALT lymphomas and is associated with aggressive disease
[1]. Molecular cloning of the breakpoint identi¢ed a novel
gene, Bcl10, which is translocated to the immunoglobulin
heavy chain locus [2,3]. The human Bcl10 gene encodes a
protein of 233 amino acids (aa) containing an N-terminal
caspase recruitment domain (CARD). Several groups have
independently characterized Bcl10 as a CARD-containing
protein displaying high homology to the equine herpes virus
gene product v-E10 [4^6]. Both v-E10 and Bcl10 contain a
highly homologous amino-terminal CARD motif that allows
for both homo- and heterodimerization of the two proteins
[4^6]. v-E10 binds TRAF3 and TRAF6, whereas its cellular
homolog Bcl10 interacts with TRAF1, 2 and 5 [4,7]. Despite
this structural homology and the capacity of both proteins to
associate with TRAFs, they di¡er in their ability to trigger
nuclear factor UB (NF-UB) activation. Overexpression of
Bcl10 results in weak NF-UB activation while v-E10 triggers
a strong response [4^6]. Bcl10 was also reported to induce
apoptosis [5,8,9], however, this function could not be con-
¢rmed in cells de¢cient in the Bcl10 protein [10]. Instead,
antigen-driven NF-UB signals and proliferation were found
to be defective in Bcl103/3 lymphocytes, corroborating the
role of Bcl10 as an important component of the NF-UB sig-
naling pathway.
While events that lead to NF-UB activation downstream of
Bcl10 have been studied and include TRAF-binding and sub-
sequent recruitment of the IKK complex [4,7,11], little is
known about the upstream activator(s) of Bcl10. Some insight
was recently obtained from the study of the molecular func-
tion of equine herpes virus protein v-E10, which activates NF-
UB via Bcl10 [12]. v-E10 is targeted to the plasma membrane
due to a geranylgeranylation consensus site at its C-terminus
and is able to recruit Bcl10 from the cytoplasm. This recruit-
ment results in the hyperphosphorylation of Bcl10 and in
activation of NF-UB.
To learn more about Bcl10’s role in the pathway that con-
nects the antigen receptor to NF-UB activation, we thought to
identify the upstream binding partner and activator of Bcl10.
Here we present the initial characterization of such a candi-
date protein, named Carma1 (CARD-MAGUK1). Similar to
v-E10, Carma1 interacts with Bcl10 via a CARD^CARD in-
teraction, induces its phosphorylation at several sites, and
provokes NF-UB activation.
2. Materials and methods
2.1. Cloning of Carma1 cDNA
EST clones encoding human Carma1 were identi¢ed in the dbEST
data base at the National Center for Biotechnology Information (EST
clones 1283 557 and 2228 571). Both clones were sequenced and EST
2228 571 was used to amplify the C-terminal portion of Carma1 (332^
1148) by polymerase chain reaction (PCR) using primers JT2110
(5P-gtatctagaggagaaggaggacctgga-3P) and JT2111 (5P-ggtctagatca cag-
ctggtcctcgtccac-3P) for the N-terminally tagged versions and using
JT2110 and JT2112 (5P-ggggatcccagctggtcctcgtccaccca-3P) for the C-
terminally tagged constructs. Other Carma1 constructs were cloned
using standard procedures.
2.2. Expression vectors
Expression vectors for v-E10 and Bcl10 with an amino-terminal
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Fig. 1. A: Amino acid sequence of Carma1. The open reading frame for Carma1 reveals the presence of a CARD motif, a CC domain, a PDZ
domain, an SH3 domain and a GUK domain (boxed areas). B: Domain organization of the Carma family (Carma 1^3, CARD9). Alignments
of (C) CARD from a selected subset of CARD-containing proteins and (D) CC domains from the Carma family members. For each block of
aligned sequences, black boxes indicate s 50% (100% for CC domains) aa sequence identity and gray shading indicates s 50% (75% for CC
domains) sequence similarity through conservative aa substitutions.
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FLAG- or VSV-tag and for dominant negative TRAF1 and IUB have
been described previously [4,13]. The point mutation in the CARD
motif (L41R) was obtained by ampli¢cation on cloned full-length
wild-type Bcl10 cDNA using standard PCR conditions and Pwo poly-
merase (Roche). The following expression plasmids were kindly ob-
tained from the indicated sources: GFP-TRAF2-DN (aa 266^501)
from H. Wajant (Stuttgart, Germany); VSV-IKKQ-DN from S.
Whiteside and A. Israel, (Paris, France), and NF-UBLuc and L-gal
reporter plasmids from V. Jongeneel (Lausanne, Switzerland).
2.3. Northern blot analysis
Northern blot analysis was performed by probing a human multiple
tissue Northern blot (Clontech), according to the manufacturer’s in-
structions, with a 32P-labeled antisense RNA probe encompassing the
N-terminal 650 nucleotides of Carma1 cDNA.
2.4. Transient cell transfection, immunoprecipitation and
NF-UB activation assays
These techniques were performed essentially as described before
[4,14]. Antibodies used for Western blotting include anti-FLAG M2
and anti-VSV P5D4 monoclonal antibodies, respectively (Sigma). Cel-
lular (endogenous) Bcl10 was detected using an a⁄nity-puri¢ed poly-
clonal rabbit antibody (AL114) directed against a peptide encompass-
Fig. 2. Tissue distribution of murine Carma1. A Northern blot of
various mouse tissues (Clontech) was probed with a 32P-labeled




Fig. 3. Interaction of Carma1 with Bcl10. A: 293T cells were co-transfected with expression vectors for various VSV-tagged constructs of Car-
ma1 and for Bcl10, as indicated, and anti-VSV immunoprecipitates were analyzed for the presence of Bcl10 by Western blotting. The expression
levels of the Bcl10 and VSV-tagged Carma1s in the cell extracts are shown below. B: 293T cells were co-transfected with an expression vector
for VSV-tagged Carma1 (aa 153) and FLAG-Bcl10 and FLAG-RAIDD. Anti-FLAG immunoprecipitates were then analyzed for the presence
of Carma1. C: Wild-type and a CARD-mutant Bcl10 were analyzed for their capacity to interact with Carma1.
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ing 24 amino-terminal aa (SLTEEDLTEVKKDALENYRVLCEK) of
murine Bcl10.
2.5. Protein dephosphorylation
Transfected 293T HEK cells from a 5.5-cm dish were lysed in 1%
NP-40 bu¡er containing 10 mM Tris^HCl pH 7.4, 150 mM NaCl,
1 mM EDTA and 0.25 Wg/ml Pefabloc0sc (Serva) on ice. Aliquots (20
Wg) of postnuclear lysates were incubated with V protein phosphatase
(New England Biolabs) in a bu¡er supplied by the manufacturer for
3 h at 30‡C.
2.6. Immunostaining and confocal laser scanning microscopy
HeLa cells were transfected with tagged constructs by the calcium
phosphate/BES method. Expressed proteins were stained with anti-
VSV (Sigma, 1/50 000) or anti-FLAG (Zymed, 0.2 Wg/ml) and subse-
quently with Cy5-labeled (Jackson ImmunoResearch Laboratories) or
Alexa-488-labeled (Molecular probes) secondary anti-mouse or anti-
rabbit antibody. Confocal microscopy was performed on a Zeiss
Axiovert 100 microscope (Zeiss Laser Scanning Microscope 510).
3. Results
3.1. Identi¢cation of Carma1 as a novel interaction partner of
Bcl10
To identify cellular proteins that possibly interact with the
CARD motif of Bcl10, we have used a bioinformatic ap-
proach, which is based on the observation that domains of
the DD-fold family (DD, DED, CARD motifs) interact best
when their respective sequences are highly similar [15]. When
we screened genomic databases with a pro¢le (Pfr: CARD)
that detects CARD-containing proteins, more than 30
CARD-containing proteins were found. Our attention was
attracted by a family of three proteins, designated Carma1,
Carma2 and Carma3, which were predicted to contain CARD
motifs that are highly homologous to the CARD of Bcl10.
The CARDs of Carma1^3 share 23, 27 and 20% identical aa
with the Bcl10 CARD, respectively (Fig. 1C), while, for com-
parison, only 16% identity is found between the CARD motif
of Bcl10 and NALP1 [16].
We have focused our interest on Carma1, since several EST
clones, covering most of the C-terminus of the predicted pro-
tein, were available for Carma1, and the missing cDNA por-
tion encoding the N-terminus could be obtained by nested
reverse transcription-PCR. Sequence analysis of the complete
cDNA clone validated the genomic sequence, predicting a
protein of 1147 aa (132 kDa) (Fig. 1A), comprising ¢ve pu-
tative functional domains (Fig. 1B): the N-terminal CARD is
followed by a region of approximately 300 aa with a predicted
coiled-coiled (CC) structure [17], a PDZ domain, an SH3 do-
main and a GUK (guanylate kinase) domain. The PDZ/SH3/
GUK domain arrangement is the signature of members of the
MAGUK (membrane-associated GUK) family, which are
sca¡olding proteins organizing macromolecular complexes at
specialized regions of the plasma membrane [18]. A similar
structural organization is also predicted for Carma2 and Car-
ma3. The N-terminal part of Carma1 (comprising the CARD
and CC domains) displays high sequence similarity with
CARD9, a protein recently reported to interact with Bcl10
[18]. Of particular interest is not only the high conservation
between the two CARD motifs of Carma1 and CARD9 (52%
identical aa) but also the high sequence similarity in the CC
region, indicating that CARD 9 is a bona ¢de member of the
Carma family (Fig. 1D). Since most cytoplasmic proteins con-
taining a CC structural motif form dimers [17], it is likely that
CARD9 (Carma4) and the other Carma family members form
homo- and/or heterodimers.
Northern blot analysis revealed that Carma1 expression
was restricted to lymphoid tissues. A single transcript of ap-
proximately 4.4 kb was predominantly found in spleen, thy-
mus and, in particular, PBLs (Fig. 2). This tissue distribution
suggests a role of Carma1 in cells of the immune system in
which Bcl10 was previously shown to play a major role in
NF-UB activation [10].
The possible interaction between Carma1 and Bcl10, sug-
gested from the relatively high degree of sequence identity
between the CARD of Bcl10 and Carma1, was examined by
co-expression of di¡erent FLAG-tagged Carma1 constructs
with VSV-tagged human Bcl10 in 293T cells, followed by
co-immunoprecipitation studies. An interaction was noted
Fig. 4. Carma1 recruits Bcl10 to perinuclear structures. HeLa cells were transfected with expression vectors for both FLAG-Bcl10 and VSV-
Carma1 and their subcellular localization determined 30 h after transfection by confocal laser microscopy, using the anti-VSV or anti-FLAG
antibodies. The overlay of Bcl10 £uorescence and Carma1 is shown in the column ‘merged’. The rightmost panels show HeLa cells that were
transfected with either construct alone. PC: Phase contrast.
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Fig. 5. NF-UB activation and Bcl10 phosphorylation by Carma1. A: 293T cells were co-transfected with an NF-UB luciferase reporter plasmid
(pNF-UBluc), L-galactosidase expression vector (pCMV L-gal), and increasing amounts (0.005, 0.05 and 0.5 Wg) of the indicated Carma1 con-
structs with FLAG-tags at their C-terminus (-F). Luciferase activities were determined 24 h after transfection and normalized on the basis of
L-galactosidase values as previously described [4]. Values shown are averages for representative experiments in which each transfection was car-
ried out in duplicate. Expression levels of Carma1 constructs are shown in the inset. B: 293T cells were co-transfected with VSV-tagged Bcl10
and increasing amounts (0.005, 0.05 and 0.5 Wg) of expression vectors for FLAG-tagged Carma1 or v-E10, respectively. Arrowheads indicate
the migration position of the non-phosphorylated and the two hyperphosphorylated forms of Bcl10. Cell extracts of transfected cells were incu-
bated for 3 h in presence or absence of V-phosphatase, as indicated. C: Inhibition of Carma1-induced NF-UB activation but not Bcl10 phos-
phorylation by dominant negative (DN) forms of IKKL TRAF1 and IkB. 293T cells were co-transfected with pNF-UBLuc, pCMV L-gal, 5 Wg
of Carma1, 5 Wg of Bcl10 and/or the indicated DN expression vectors. Samples were analyzed for luciferase activity (left panel) and phosphory-
lation of Bcl10 (right panel). Expression levels of the transfected proteins are shown in the lower right panel.
FEBS 24842 4-5-01
O. Gaide et al./FEBS Letters 496 (2001) 121^127 125
only between Carma1 and Bcl10 (Fig. 3A), while RAIDD,
caspase-1, -2, -4 and -9, v-E10 or CARDIAK (RIP2) did
not interact (Fig. 3B and data not shown). Carma1 did not
interact with a mutant Bcl10 whose CARD motif was mu-
tated such that it had lost the capacity to interact with other
CARDs [5,6,9,12], indicating that the interaction was CARD-
dependent. We were unable to detect an interaction of Car-
ma1 with v-E10 (data not shown).
Association of Carma1 with Bcl10 could also be followed
by confocal microscopy. Overexpression of Bcl10 in HeLa
cells resulted in a di¡use cytoplasmic staining, in agreement
with our previous observation [12] (Fig. 4). Carma1, in con-
trast, showed a granular perinuclear staining. Upon co-expres-
sion with Carma1, most of the cytoplasmic staining of Bcl10
disappeared and Bcl10 now co-localized with Carma1 to peri-
nuclear structures. Taken together, our results demonstrate
that Carma1, via its CARD motif, associates with Bcl10.
3.2. Activation of NF-UB by Carma1
Since Bcl10 plays a major role in the NF-UB signaling path-
way in lymphocytes [10], we next investigated the capacity of
full-length Carma1 and two truncated forms thereof (Carma1-
short, containing roughly the CARD motif, and Carma1-long
containing the CARD motif and most of the CC domain, see
Fig. 5A) to activate the NF-UB luciferase reporter plasmid in
293T cells. Expression of full-length and of Carma1-CARD-
CC in 293T cells (which contain endogenous Bcl10, data not
shown) resulted in an up to 10-fold increase of the reporter
gene (Fig. 5A) and was comparable to the capacity of v-E10
to activate this transcription factor. The CARD motif of Car-
ma1 alone was su⁄cient for NF-UB activation, albeit at re-
duced e⁄ciency. DN-IKK2, DN-IUB and DN-TRAF1, but
not DN-TRAF2 (which does not bind Bcl10 in our hands
[4]), inhibited Carma1-mediated NF-UB activation (Fig. 5B).
Together, these results indicate that Carma1, akin to v-E10,
initiates the NF-UB signaling cascade upstream of TRAF1
and the IKK signalosome [4,11].
3.3. Carma1 induces phosphorylation of Bcl10
v-E10-induced NF-UB induction leads to the formation of
hyperphosphorylated forms of Bcl10 (Fig. 5C) [4]. We there-
fore investigated whether Carma1 induces phosphorylation of
Bcl10. When expressed alone, Bcl10 was mostly in its non-
phosphorylated form (Fig. 5C), while in the presence of in-
creased levels of Carma1, a phosphorylation pattern of Bcl10
identical to the one induced by v-E10, i.e. the unphosphory-
lated (30 kDa) and two slower migrating species (34 and 38
kDa) was observed. These latter two bands correspond to
phosphorylated forms as shown by treatment of the lysates
with V-phosphatase (Fig. 5C). DN-IKK2, DN-IUB and DN-
TRAF1 did not inhibit Bcl10 phosphorylation (Fig. 5B), sug-
gesting that Bcl10 phosphorylation occurs upstream or in
parallel to TRAF1/IKK2-dependent NF-UB induction by
Carma1.
4. Discussion
We have identi¢ed Carma1 as a CARD-containing member
of the MAGUK family and interaction partner of Bcl10.
Overexpression of Carma1 results in a CARD-dependent as-
sociation with Bcl10 and induces phosphorylation of Bcl10
and NF-UB activation. In this respect, Carma1 behaves like
v-E10. Phosphorylation of Bcl10 and activation of NF-UB by
v-E10 is dependent on Bcl10 translocation from the cytoplasm
to the membrane [12]. Carma1, on the other hand, localizes to
perinuclear structures in epithelial cells and Bcl10 translocates
to these structures when co-expressed with Carma1. This is in
complete agreement with a study published during the prepa-
ration of our manuscript [19]. It is probable that this trans-
location triggers Bcl10 to signal NF-UB, but it remains to be
seen whether complex formation between Carma1 and Bcl10
in perinuclear structures also occurs in lymphocytes, to which
Carma1 expression appears to be restricted. In T-cells, Car-
ma1 and Bcl10 may co-localize in the zone of the immuno-
logical synapse where T-cell receptors are being stimulated by
antigen-presenting cells. Such a model is suggested from the
structural organization of Carma1 identifying it as a member
of the MAGUK family. MAGUK members are sca¡olding
proteins that organize macromolecular complexes at special-
ized regions of the plasma membrane [18]. MAGUKs possess
a characteristic domain structure: one or more PDZ do-
main(s), an SH3 domain and a GUK domain at the C termi-
nus. PDZ and SH3 domains are well established as protein-
binding structures, the former recognizing peptide ligands,
usually at the C terminus of target proteins, and the latter
recognizing proline-rich peptide motifs. In addition, most
MAGUKs contain a motif rich in basic residues which medi-
ates binding to protein 4.1 and/or other ezrin^radixin^moesin
family proteins, thus providing anchorage to the cortical actin
network. Reorganization of the cortical cytoskeleton is a hall-
mark of T lymphocyte activation occurring during the forma-
tion of the immunological synapse [20]. Thus, it is conceivable
that in the immunological synapse, Carma1 plays a role as a
modulator of signaling pathways that exist between the T-cell
receptor and the cytoskeleton.
Translocation and upregulation of Bcl10 in MALT tumors
conceivably mimics antigen receptor signaling by constitu-
tively activating NF-UB, thereby promoting antigen-indepen-
dent growth and lymphoma progression. Another MALT
lymphoma translocation, t(11;18)(q21;q21), fuses the IAP-2
gene to the MLT1/MALT1 locus [21^23], which encodes the
human MLT protein. This fusion activates NF-UB and inter-
estingly, the MLT protein directly interacts with Bcl10 [24],
indicating that MLT and Bcl10 are components of the same
signaling pathway. Bcl10 regulates lymphocyte proliferation,
and its requirement for NF-UB signaling suggests a mecha-
nism for the oncogenic e¡ect. Activation of NF-UB signaling
either through mutation of rel genes and their upstream reg-
ulators or by expression of viral oncogenes has been impli-
cated in a range of hematopoietic tumor types. The precise
knowledge of the Carma1/Bcl10-dependent NF-UB pathway
will therefore be of utmost importance for cancer therapy.
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